Skip to main content

HOOK

Stock
Health Care
Biotechnology

Performance overview

HOOK Price
Price Chart

Forward-looking statistics

Beta
1.38
Risk
80.33%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.

Company info

SectorHealth Care
IndustryBiotechnology
Employees128
Market cap$81.0M

Fundamentals

Enterprise value-$23.8M
Revenue$9.4M
Revenue per employee
Profit margin0.00%
Debt to equity1.75

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$5.85
Dividend per share
Revenue per share$0.75
Avg trading volume (30 day)$151K
Avg trading volume (10 day)$61K
Put-call ratio

Macro factor sensitivity

Growth-2.2
Credit+4.6
Liquidity+0.9
Inflation-5.2
Commodities-1.1
Interest Rates+0.5

Valuation

Dividend yield0.00%
PEG Ratio-0.23
Price to sales1.60
P/E Ratio-0.23
Enterprise Value to Revenue-2.54
Price to book0.45

Upcoming events

Next earnings dayMay 16, 2025
Next dividend day
Ex. dividend day

News

Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet

The mean of analysts' price targets for HOOKIPA Pharma (HOOK) points to a 622.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research (September 2, 2024)
Hookipa Shares Jump On New Preclinical Data On Cancer Immunotherapies

HOOKIPA Pharma Inc (NASDAQ: HOOK) has announced preclinical data demonstrating potent T cell responses, combination use beyond PD-1 inhibitors, and the ability to break immune tolerance to various self-antigens for targeting cancers.  Preclinical data show that combining co-.

Benzinga (April 13, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free